MedTrace Logo

PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK

NCT02778607 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2020-10-19

No results posted yet for this study

Summary

Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments. To aid the development of new treatment trials, there is a pressing need to develop better methods for diagnosing these conditions early, and to track disease progression. The PROSPECT-M-UK study will collect standardised clinical data over time. Patients will also have the option to have a brain MRI scan, eye movement exam and donate blood, skin and spinal fluid samples, with the aim to identify "biomarkers" that can improve the accuracy of early diagnosis and track the natural time course of disease. Control participants and those not meeting criteria for Parkinson's disease or other defined conditions but are considered by the investigator group to be allied syndromes or at risk states (atypical parkinsonian syndromes), will also be examined. Patients can also participate via the CBD European registry or in a one-off study assessment through the cross-sectional study, which involves completing questionnaires and a blood sample donation.

Conditions

  • Progressive Supranuclear Palsy (PSP)
  • Corticobasal Degeneration
  • Multiple System Atrophy (MSA)

Sponsors & Collaborators

  • University of Cambridge

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Manchester

    collaborator OTHER

  • Newcastle University

    collaborator OTHER

  • University of Sussex

    collaborator OTHER

  • Royal Gwent Hospital

    collaborator UNKNOWN

  • University College, London

    lead OTHER

Principal Investigators

  • Huw Morris, PhD, FRCP · University College, London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02778607 on ClinicalTrials.gov